Wednesday, 25 March 2015

Patent Translation - Why It is neccesary

Lawful Cases That Demonstrate the Need for Professional Translators

An improper translation submitted to the USPTO may narrow the scope of the patent claim, since the mistranslation will specify an amendment to the patent write-down. We’ll look at two further court cases that highlight the outcomes of using low-quality translations for legal purposes. You might risk owning your translation refused during the court case as a result of a poor translation method or questionable translator qualification. You may also risk the invalidation of the patent statements due to the insufficient translation of a large chunk of prior art.

A crucial claim in the patent might be invalidated due to an inadequate translation of a particular sentence in a sheet of prior art. For instance, in the case of Mitsubishi Chemical Organization, et al. v Barr Laboratories, Inc. and Pliva-Hrvatska D.O.O., the interpretation of the translation for a single sentence from a piece of prior art determined the validity of contested statements. A patent translation is more likely to be found reliable by the court if a documented quality process is followed to create the translation. In the Mitsubishi situation, the court refused the translations provided by the defendant due to errors that occurred during the translation method.


A court may reject a patent translation that isn’t created by a fully competent translator with demonstrated credentials. In the case of On Demand Product Corporation v. Ingram Industries,  et al. the court states that in order for the Japan application to be looked at as prior art evidence by the court, it has got to be translated by a verifiably qualified translator.

Searching For patent Translation Company .. You can Submit your query or go to Website.

Related Links :
You may also be interested in :




Thursday, 10 July 2014

Patent Expiration of Rilutek to Cause Negative Growth in Amyotrophic Lateral Sclerosis Treatment Market by 2018

Patent Expiration of Rilutek to Cause Negative Growth in Amyotrophic Lateral Sclerosis Treatment Market by 2018 is a new market research publication announced by Reportstack. The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013 to $38 million by 2018, at a negative Compound Annual Growth Rate (CAGR) of 10.05%.

The company’s latest report states that the largest factor in this decline, which will occur over seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan), will be the patent expiration of Rilutek (riluzole), the only approved therapy for ALS.

As a consequence, it forecasts that the ALS treatment market in the US is set to suffer a substantial reduction in sales over the forecast period, from $38 million in 2013 to $16 million by 2020, at a negative CAGR of 16.10%.

http://www.whatech.com/members-news/reports-industrial/23749-patent-expiration-of-rilutek-to-cause-negative-growth-in-amyotrophic-lateral-sclerosis-treatment-market-by-2018

Wednesday, 2 July 2014

MyScript® To Bring Power Of Handwriting To iOS 8

MyScript®, the acknowledged market leader in accurate, high-performance handwriting recognition and digital ink management technology, announces the support of MyScript handwriting recognition technology for iOS 8.
MyScript technology provides a versatile and natural way for users to leverage handwritten input on iOS devices. For the upcoming iOS 8 release, MyScript is readying two input panel applications that offer user friendly alternatives to keyboard entry. The apps will be available on the App Store. The core technology can be leveraged by developers to create applications for iOS 8 including note-taking applications, music notation programs, education applications, games and more.
The first input panel application in development for iOS 8 allows real-time text input using fingertip and stylus. The auto scrolling input panel will provide an alternative to onscreen and physical keyboard in any application requiring text entry such as email, text editor, calendar, web browser, SMS, MMS, etc. Handwritten input will be converted into digital text in real time in the active application. The input panel will allow the user to leverage intuitive gestures for easy editing. Words and sentences will be quickly moved, split, joined, overwritten, and erased. To help users write long words and phrases, the writing area will scroll over progressively.
The second app under development for iOS 8 allows superimposed character input. This input panel allows users to continuously and quickly write characters on top of each other, making short text entry convenient and efficient. Users will be able to easily input phone numbers, look up names in address books, compose tweets, and write chat or SMS messages with their fingertips. Handwriting will be captured at rotations up to 40°, allowing for greater flexibility for mobile users. The handwritten input will be instantly recognized, converted to digital text, and sent to the target application.


Read more: http://www.digitaljournal.com/pr/2028131#ixzz36ILY7qdx

Tuesday, 1 July 2014

MasterCard Patent Would Add Bitcoin To Global Shopping Cart

http://seekingalpha.com/article/2293465-mastercard-patent-would-add-bitcoin-to-global-shopping-cart


Global financial services giant MasterCard (MA) has filed a patent that would seek to incorporate bitcoin into its design for a planned global online shopping cart.
Entitled 'Payment Interchange For Use With Global Shopping Cart', the filing was submitted by the New York company to the U.S. Patent and Trademark Office (USPTO) in March 2013.
The patent application is part of a series of filings related to MasterCard's effort to build a global online shopping cart catering to online shoppers.
This global shopping cart would be based on each store offering its own individual cart, thereby making it easier for consumers to dedicate carts to larger projects, such as weddings or home renovations.

Monday, 16 June 2014

Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or "'277 patent") in the company's McSwiggen patent estate. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the '277 patent includes claims that the company believes are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection. This patent is held exclusively by Alnylam and is not licensed to any third parties. The McSwiggen patent estate comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck.
"We are pleased with the USPTO's decision to issue the '277 patent from our McSwiggen patent family, a key component of the IP estate we recently obtained through our acquisition of Sirna Therapeutics from Merck. Our '277 patent has broad, sequence-independent claims on chemically modified siRNAs which we believe are critical for the development and commercialization of RNAi therapeutics for the treatment of HBV infection," said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam. "Our IP estate remains a cornerstone in our efforts to advance RNAi therapeutics to patients in need. In the case of the '277 patent, we intend to maximize the value of this newly issued IP solely through the advancement of ALN-HBV -- our GalNAc-conjugated siRNA targeting the HBV genome for the treatment of HBV infection -- where we expect to select our Development Candidate by this year's end and to file an investigational new drug application at or around year-end 2015."


http://online.wsj.com/article/PR-CO-20140612-905682.html

Thursday, 12 June 2014

Catalyst Files Patent for Next-Generation Technology Assisted Review Based on 'Reinforcement Learning'

 Catalyst Repository Systems -- a pioneer in developing secure, cloud-based software to help corporations and their law firms take control of e-discovery, compliance and regulatory matters -- today announced it has applied for a patent on the type of continuous learning capability it invented for its next-generation technology assisted review (TAR 2.0) platform, Insight Predict.
Described in the patent application as "reinforcement learning based document coding," Catalyst's TAR technology is able to continuously learn from actions taken by the review team throughout the review process. With reinforcement learning, certain actions -- such as coding a document as responsive or not or adding additional documents -- enable the system to continue to grow "smarter" in its ability to select relevant documents.
What is Reinforcement Learning?
Reinforcement learning differs from older TAR 1.0 systems which require training by a high-level attorney. This expensive and time-consuming approach requires the senior attorney to first review and code an initial training set of randomly selected documents. With Catalyst's reinforcement learning technology, the full review team can begin right away. As reviewers' judgments are fed back into the system and new documents added, the system's selection and ranking of relevant documents continuously improves.
A new, peer-reviewed study by two leading experts in e-discovery validates the effectiveness of continuous learning technologies in e-discovery. In a paper they will present at the Association of Computing Machinery Special Interest Group on Information Retrieval (SIGIR) international conference in July 2014, "Evaluation of Machine-Learning Protocols for Technology-Assisted Review in Electronic Discovery," Gordon V. Cormack and Maura R. Grossman conclude that non-random training methods using continuous active learning "require substantially and significantly less human review effort" and yield "generally superior results."

http://www.marketwatch.com/story/catalyst-files-patent-for-next-generation-technology-assisted-review-based-on-reinforcement-learning-2014-06-11

Wednesday, 11 June 2014

Unify Wins 2014 World Trademark Review Industry Award

 Unify today announced the company's in-house counsel team was named a winner in the 2014 Industry Awards presented by World Trademark Review (WTR), the world's only independent international magazine dedicated exclusively to trademark law and practice.
The winners were announced on May 13, 2014, during theInternational Trademark Association's annual meeting at the Happy Valley Racecourse in Hong Kong. The event was attended by more than 200 senior in-house counsel from nominated companies and representatives from a number of prominent law firms.
"Trademarks are a key corporate asset and those tasked with protecting and enhancing the value of these critical rights contribute directly to their company's success," saidTrevor Little, editor of WTR. "Yet, too often trademark counsel are unsung corporate heroes and it is vitally important that the work they undertake is recognized. All of this year's shortlisted teams and individuals represent the best in class. This made judging the awards a very difficult process and the winners really do represent best practice in the trademark industry, and deserve special recognition for their exceptional achievements."

http://www.broadwayworld.com/bwwgeeks/article/Unify-Wins-2014-World-Trademark-Review-Industry-Award-20140611#.U5hhCnKSyIo